1-2 of 2
Bradley James Sumrow
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Mivavotinib, a Syk Inhibitor, in Relapsed/Refractory (R/R) Non-GCB Diffuse Large B-Cell Lymphoma (DLBCL) with or without MYD88 and/or CD79 Mutations: A Phase 2 Study

Reem Karmali, Daniel J. Landsburg, Jason Westin, John P. Leonard, Emil T. Kuriakose, Bradley James Sumrow, Susheela Carroll, Katherine Albert, Lalith Akella, Leo I. Gordon
Journal: Blood
Blood (2022) 140 (Supplement 1): 12125–12126.
https://doi.org/10.1182/blood-2022-165502
Published: 2022
Journal Articles

A Phase 1, Open-Label Study of MGD013, a Bispecific DART ® Molecule Binding PD-1 and LAG-3 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Jie Wang, MD, Adam S. Asch, MD, Nada Hamad, MBBS,BSc,MSc,FRACP FRCPA, Andrew Weickhardt, MBBS(Hons) FRACP DMedSc, Monika Tomaszewska-Kiecana, Monika Dlugosz-Danecka, MD PhD, Halyna Pylypenko, MD, Shakeela Bahadur, MD, Susanna Ulahannan, MD MMed, Janine Koucheki, Jichao Sun, PhD, Hua Li, Francine Chen, MD, Xiaoyu Zhang, John Muth, MS, Patrick Kaminker, PhD, Paul Moore, PhD, Bradley James Sumrow, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 21–22.
https://doi.org/10.1182/blood-2020-139868
Published: 2020